Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?

BACKGROUND: Cytarabine use during pregnancy carries a 5–7% risk of neonatal cytopenia. We report two cases of fetal myelosuppression following high-dose cytarabine administration for acute myeloid leukemia (AML). CASE 1: A 36-year-old G9P6 diagnosed with AML at 21 weeks was monitored for fetal anemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrott, Jessica, Holland, Marium
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623771/
https://www.ncbi.nlm.nih.gov/pubmed/29075543
http://dx.doi.org/10.1155/2017/5175629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623771/
https://www.ncbi.nlm.nih.gov/pubmed/29075543
http://dx.doi.org/10.1155/2017/5175629

Ejemplares similares